AMG 193 Effective in Multiple Tumor Types
Unknown authors
Abstract
In a phase I trial of the MTA-cooperative PRMT5 inhibitor AMG 193, five of 39 patients with advanced MTAP-deleted solid tumors who had scans following initial treatment experienced partial responses. The responses occurred in five tumor types-esophageal, pancreatic, renal cell, gallbladder, and ovarian Sertoli-Leydig cell cancer.
Topics & Concepts
Pancreatic cancerMedicineCancer researchInternal medicineGallbladder cancerEsophageal cancerCellGallbladderCancerOncologyPathologyBiologyBiochemistryCancer-related gene regulationDiabetes Treatment and ManagementCoagulation, Bradykinin, Polyphosphates, and Angioedema